• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同时表达四个和八个多重向导 RNA 和 Cas9 尼克酶的一体式腺病毒载体的构建和稳定性。

Construction and Stability of All-in-One Adenovirus Vectors Simultaneously Expressing Four and Eight Multiplex Guide RNAs and Cas9 Nickase.

机构信息

Department of Immune Medicine, National Cancer Center Research Institute, Tokyo 104-0045, Japan.

Laboratory of Virology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Foundation, Shinagawa-ku, Tokyo 141-0021, Japan.

出版信息

Int J Mol Sci. 2024 Aug 12;25(16):8783. doi: 10.3390/ijms25168783.

DOI:10.3390/ijms25168783
PMID:39201470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11354445/
Abstract

CRISPR/Cas9 technology is expected to offer novel genome editing-related therapies for various diseases. We previously showed that an adenovirus vector (AdV) possessing eight expression units of multiplex guide RNAs (gRNAs) was obtained with no deletion of these units. Here, we attempted to construct "all-in-one" AdVs possessing expression units of four and eight gRNAs with Cas9 nickase, although we expected obstacles to obtain complete all-in-one AdVs. The first expected obstacle was that extremely high copies of viral genomes during replication may cause severe off-target cleavages of host cells and induce homologous recombination. However, surprisingly, four units in the all-in-one AdV genome were maintained completely intact. Second, for the all-in-one AdV containing eight gRNA units, we enlarged the E3 deletion in the vector backbone and shortened the U6 promoter of the gRNA expression units to shorten the AdV genome within the adenovirus packaging limits. The final size of the all-in-one AdV genome containing eight gRNA units still slightly exceeded the reported upper limit. Nevertheless, approximately one-third of the eight units remained intact, even upon preparation for in vivo experiments. Third, the genome editing efficiency unexpectedly decreased upon enlarging the E3 deletion. Our results suggested that complete all-in-one AdVs containing four gRNA units could be obtained if the problem of the low genome editing efficiency is solved, and those containing even eight gRNA units could be obtained if the obstacle of the vector size is also removed.

摘要

CRISPR/Cas9 技术有望为各种疾病提供新型的与基因组编辑相关的治疗方法。我们之前曾表明,获得了一种具有八个多重向导 RNA(gRNA)表达单元的腺病毒载体(AdV),而这些单元没有缺失。在这里,我们试图构建具有 Cas9 切口酶的四个和八个 gRNA 表达单元的“一体式”AdV,尽管我们预计获得完整的一体式 AdV 会存在障碍。第一个预期的障碍是,在复制过程中病毒基因组的极高拷贝数可能导致宿主细胞的严重非靶向切割,并诱导同源重组。然而,令人惊讶的是,一体式 AdV 基因组中的四个单元完全保持完整。其次,对于含有八个 gRNA 单元的一体式 AdV,我们扩大了载体骨架中的 E3 缺失,并缩短了 gRNA 表达单元的 U6 启动子,以缩短腺病毒包装限制内的 AdV 基因组。含有八个 gRNA 单元的一体式 AdV 基因组的最终大小仍然略高于报道的上限。尽管如此,在准备体内实验时,大约三分之一的八个单元仍然保持完整。第三,扩大 E3 缺失会导致基因组编辑效率意外降低。我们的结果表明,如果解决了低基因组编辑效率的问题,就可以获得包含四个 gRNA 单元的完整一体式 AdV,而如果消除了载体大小的障碍,也可以获得包含甚至八个 gRNA 单元的一体式 AdV。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/8169a563d19a/ijms-25-08783-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/bed6cb209594/ijms-25-08783-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/b8fa86f219a1/ijms-25-08783-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/3786537d0f71/ijms-25-08783-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/3b84da9462b2/ijms-25-08783-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/4a9e8f85da55/ijms-25-08783-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/192e62021d07/ijms-25-08783-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/8169a563d19a/ijms-25-08783-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/bed6cb209594/ijms-25-08783-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/b8fa86f219a1/ijms-25-08783-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/3786537d0f71/ijms-25-08783-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/3b84da9462b2/ijms-25-08783-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/4a9e8f85da55/ijms-25-08783-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/192e62021d07/ijms-25-08783-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d005/11354445/8169a563d19a/ijms-25-08783-g007.jpg

相似文献

1
Construction and Stability of All-in-One Adenovirus Vectors Simultaneously Expressing Four and Eight Multiplex Guide RNAs and Cas9 Nickase.同时表达四个和八个多重向导 RNA 和 Cas9 尼克酶的一体式腺病毒载体的构建和稳定性。
Int J Mol Sci. 2024 Aug 12;25(16):8783. doi: 10.3390/ijms25168783.
2
Construction of adenovirus vectors simultaneously expressing four multiplex, double-nicking guide RNAs of CRISPR/Cas9 and in vivo genome editing.构建同时表达 CRISPR/Cas9 的四个多重、双切口向导 RNA 的腺病毒载体及体内基因组编辑。
Sci Rep. 2021 Feb 17;11(1):3961. doi: 10.1038/s41598-021-83259-0.
3
Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.腺病毒载体表达 CRISPR/Cas9 的八个多重引导 RNA 可有效破坏来自不同患者的乙型肝炎病毒基因。
Int J Mol Sci. 2021 Sep 29;22(19):10570. doi: 10.3390/ijms221910570.
4
Highly multiplex guide RNA expression units of CRISPR/Cas9 were completely stable using cosmid amplification in a novel polygonal structure.采用新型多边形结构的 cosmid 扩增技术,可实现 CRISPR/Cas9 中高度多重靶向的 guide RNA 表达单元的完全稳定。
J Gene Med. 2019 Nov;21(11):e3115. doi: 10.1002/jgm.3115. Epub 2019 Oct 29.
5
Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.基因治疗与 CRISPR/Cas9 渐趋成熟,有望攻克 HIV。
AIDS Rev. 2017 Oct-Dec;19(3):167-172.
6
A protocol for custom CRISPR Cas9 donor vector construction to truncate genes in mammalian cells using pcDNA3 backbone.使用 pcDNA3 骨架在哺乳动物细胞中截断基因的定制 CRISPR Cas9 供体载体构建协议。
BMC Mol Biol. 2018 Mar 14;19(1):3. doi: 10.1186/s12867-018-0105-8.
7
A lentivirus-based system for Cas9/gRNA expression and subsequent removal by Cre-mediated recombination.基于慢病毒的 Cas9/gRNA 表达系统,以及随后通过 Cre 介导的重组进行去除。
Methods. 2019 Mar 1;156:79-84. doi: 10.1016/j.ymeth.2018.12.006. Epub 2018 Dec 19.
8
CRISPR-Cas9 system-driven site-specific selection pressure on Herpes simplex virus genomes.CRISPR-Cas9 系统驱动单纯疱疹病毒基因组的位点特异性选择压力。
Virus Res. 2018 Jan 15;244:286-295. doi: 10.1016/j.virusres.2017.03.010. Epub 2017 Mar 6.
9
Efficient Genome Editing Achieved via Plug-and-Play Adenovirus Piggyback Transport of Cas9/gRNA Complex on Viral Capsid Surface.通过将 Cas9/gRNA 复合物连接到病毒衣壳表面的腺病毒载体的即插即用,实现高效基因组编辑。
ACS Nano. 2022 Jul 26;16(7):10443-10455. doi: 10.1021/acsnano.2c00909. Epub 2022 Jun 24.
10
Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.多重串联的猴免疫缺陷病毒特异性 RNA 引导的 Cas9 切口酶使前病毒 DNA 失活。
J Virol. 2021 Nov 9;95(23):e0088221. doi: 10.1128/JVI.00882-21. Epub 2021 Sep 22.

引用本文的文献

1
Disruption of Human Papillomavirus 16 E6/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking Guide RNAs.使用表达八个双切口导向RNA的一体化腺病毒载体破坏人乳头瘤病毒16 E6/E7基因
Int J Mol Sci. 2025 Sep 5;26(17):8685. doi: 10.3390/ijms26178685.

本文引用的文献

1
Utilizing adeno-associated virus as a vector in treating genetic disorders or human cancers.利用腺相关病毒作为载体治疗遗传疾病或人类癌症。
IUBMB Life. 2024 Dec;76(12):1000-1010. doi: 10.1002/iub.2896. Epub 2024 Jul 6.
2
Adeno-associated virus as a delivery vector for gene therapy of human diseases.腺相关病毒作为人类疾病基因治疗的递送载体。
Signal Transduct Target Ther. 2024 Apr 3;9(1):78. doi: 10.1038/s41392-024-01780-w.
3
Clinical Pharmacology Perspective on Development of Adeno-Associated Virus Vector-Based Retina Gene Therapy.
腺相关病毒载体视网膜基因治疗的临床药理学观点。
Clin Pharmacol Ther. 2024 Jun;115(6):1212-1232. doi: 10.1002/cpt.3230. Epub 2024 Mar 7.
4
Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors.当前基因治疗罕见儿科疾病的局限性:从 AAV 载体的临床经验中吸取的教训。
Arch Pediatr. 2023 Nov;30(8S1):8S46-8S52. doi: 10.1016/S0929-693X(23)00227-0.
5
Genome editing for sickle cell disease: still time to correct?镰状细胞病的基因组编辑:还有时间进行纠正吗?
Front Pediatr. 2023 Nov 2;11:1249275. doi: 10.3389/fped.2023.1249275. eCollection 2023.
6
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.基于 CRISPR/Cas 的基因编辑在治疗β-地中海贫血症的策略中的应用。
Hum Genet. 2023 Dec;142(12):1677-1703. doi: 10.1007/s00439-023-02610-9. Epub 2023 Oct 25.
7
Construction and application of adenoviral vectors.腺病毒载体的构建与应用
Mol Ther Nucleic Acids. 2023 Sep 9;34:102027. doi: 10.1016/j.omtn.2023.09.004. eCollection 2023 Dec 12.
8
Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy.用于人类基因治疗的安全有效优化腺相关病毒载体开发的原理与策略
Mol Ther Nucleic Acids. 2023 May 17;32:949-959. doi: 10.1016/j.omtn.2023.05.014. eCollection 2023 Jun 13.
9
CRISPR/Cas9 for hepatitis B virus infection treatment.CRISPR/Cas9 用于乙型肝炎病毒感染的治疗。
Immun Inflamm Dis. 2023 May;11(5):e866. doi: 10.1002/iid3.866.
10
CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.CRISPR 编辑疗法治疗杜氏肌营养不良症。
Hum Gene Ther. 2023 May;34(9-10):379-387. doi: 10.1089/hum.2023.053.